- Rare disease biotech Beren adds $300M from new financingsAnxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug. The biotech announced Wednesday that it raised $135 ...Endpoints · 1mo ago↗ source
- Parabilis CEO Mathai Mammen on biotech's record IPOParabilis Medicines cemented the largest biotech IPO in industry history on Wednesday with its $670 million debut on the Nasdaq. But the Cambridge, MA-based drug developer won't be celebrating at…Endpoints · 1mo ago↗ source
- Novartis and Orionis strike second molecular glue deal for $40M upfrontNovartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones. The Boston and Belgian biotech will ...